(Q41607594)

5 October 2017

1 reference

title

Gabapentin for treatment of epilepsy in children (English)

1 reference

5 October 2017

0 references

G L Holmes

1

1 reference

5 October 2017

publication date

1 September 1997

1 reference

Seminars in pediatric neurology

5 October 2017

published in

1 reference

5 October 2017

volume

4

1 reference

5 October 2017

issue

3

1 reference

5 October 2017

page(s)

244-250

1 reference

Gabapentin: a new agent for the management of epilepsy

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Mechanisms of action of currently prescribed and newly developed antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Important pharmacokinetic properties of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

[3H]gabapentin may label a system-L-like neutral amino acid carrier in brain

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Clinical pharmacokinetics of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

1 reference

7 January 2021

Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Efficacy of gabapentin therapy in children with refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Pharmacokinetics of gabapentin in subjects with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin as an antiepileptic drug in man

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Double-blind study of Gabapentin in the treatment of partial seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Lack of interaction of gabapentin with carbamazepine or valproate

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Long-term study with gabapentin in patients with drug-resistant epileptic seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Efficacy and tolerance of long-term, high-dose gabapentin: additional observations

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Long-term treatment with gabapentin for partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin toxicity in children manifesting as behavioral changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin associated with aggressive behavior in pediatric patients with seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Behavioral side effects of gabapentin in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Hypomania induced by gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980041-1

7 January 2021

10.1016/S1071-9091(97)80041-1

Identifiers

DOI

1 reference

5 October 2017

1 reference